Clinical Trial Search

Primary: Response Rate — 0; 0; 1; 0 participants

Primary: the Number of Lymph Nodes: 1. Identified Within Each Lymph Node Group, 2.Located Within the Submandibular Gland, and 3. Within the Fibrofatty Contents Lying Deep to the…

Primary: Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy — 0; 0; 18; 13 Participants

Primary: Response Rate — 1; 2; 23; 3 Participants

Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 — 3; 1; 2; 6 Participants

Primary: Best Overall Response Rate — 2; 5; 17; 8 Participants

Primary: Pre-treatment OSCC Morphology and PDPN Expression — 2.8; 3.4; 2.5 score on a scale from 1 to 5 — p=<0.05

Primary: Number of Patients Scored as Having the Surgical Technique of Submandibular Salivary Gland Transfer Performed "Per Protocol" — 34 participants

Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants

Primary: Sentinel Lymph Node Positivity — 2 Participants

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 1; 1; 0; 1 Participants

Primary: 1-year Local Control — NA; NA months

Primary: Local Control Rate — 1; 5 Participants

Primary: MTD of Ultratrace Iobenguane I 131 — 8 mCi/kg

Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants

Primary: Pathologic Response. — 25; 2; 4; 4 Participants

Primary: Tumor Progression — 0; 0; 7; 4 Participants

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response…

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After…

Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants

Primary: Overall Response Rate — 0; 3; 25; 4 Participants

Primary: Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) — 0; 0 Participants

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants

Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants

Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes